Name：DU Yu

Department：Department of Biotechnology

Tel: (8610)63165266

Email: duyu@imb.pumc.edu.cn

Education & Research Experience

2016/09 – Now Associate research professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2011/09–2015/09 Assistant research professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2008/09–2011/07 Ph.D. in microbial and biochemical pharmacy, Peking Union Medical College

2005/09–2008/06 Master's degree in microbial and biochemical pharmacy, China Pharmaceutical University

Research Field：

New Potential Drug Target for The Prevention of Atherosclerosis

Research Interests：

1. Constructing drug screening models targeting lipid metabolism and perform HTS on large compound libraries to normalize the dyslipidemia and reduce the risk for cardiovascular events.

2. Elucidating the direct molecular targets of the above candidates, providing new ideas for the treatment of atherosclerotic cardiovascular diseases.

3. Exploring the role of intestinal microbiota and its metabolites in cardiometabolic disease, understanding mechanisms of novel therapeutic strategies through directly targeting the gut microbiome to improve cardiovascular outcomes.

Selected Publications：

1. Yu Du, Xingxing Li, Chunyan Su, Mei Xi, Xiumin Zhang, Zhibo Jiang, Li Wang and Bin Hong*. Butyrate Protects Against High-Fat Diet-Induced Atherosclerosis via Up-Regulating ABCA1 Expression in Apolipoprotein E-deficiency Mice. British Journal of Pharmacology, 2020, 177(8):1754-1772.

2. Yu Du^#, Xingxing Li^#, Chunyan Su, Li Wang, Jiandong Jiang* and Bin Hong*. The Human Gut Microbiome - A New and Exciting Avenue in Cardiovascular Drug Discovery. Expert Opinion on Drug Discovery, 2019, 14(10):1037-1052.

3. Yu Du, Li Wang, Bin Hong*. High-density Lipoprotein-Based Drug Discovery for Treatment of Atherosclerosis. Expert Opinion on Drug Discovery, 2015, 10(7):841-855.

4. Yu Du, Li Wang, Shuyi Si, Yuan Yang*, Bin Hong*. A Novel Compound 4010B-30 Upregulates Apolipoprotein A-I Gene Expression Through Activation of PPARγ in HepG2 Cells. Atherosclerosis, 2015, 239(2):589-598.

5. Xiao-Jian Jia, Yu Du, Hua-Jun Jiang, Yong-Zhen Li, Yan-Ni Xu, Shu-Yi S, Li Wang*, Bin Hong*. Identification of Novel Compounds Enhancing SR-BI mRNA Stability Through High-Throughput Screening. SLAS Discovery, 2020, 25(4):397-408.

6. Xuelei Wang, Xiaofang Chen, Xiumin Zhang, Chunyan Su, Mengxia Yang, Wei He, Yu Du, Shuyi Si, Li Wang*, Bin Hong*. A Small-Molecule Inhibitor of PCSK9 Transcription Ameliorates Atherosclerosis Through the Modulation of FoxO1/3 and HNF1α. EBioMedicine, 2020, 52, 102650.

7. Fan Yang, Yu Du, Jin Zhang, Zhibo Jiang, Li Wang*, Bin Hong*. Low-density Lipoprotein Upregulate SR-BI Through Sp1 Ser702 Phosphorylation in Hepatic Cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2016, 1861(9 Pt A):1066-1075.

8. Huajun Jiang#, Jin Zhang#, Yu Du, Xiaojian Jia, Fan Yang, Shuyi Si, Li Wang*, Bin Hong*. microRNA-185 Modulates Low Density Lipoprotein Receptor Expression as a Key Posttranscriptional Regulator. Atherosclerosis, 2015, 243(2):523-532.